Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frankel

Showing results (161-170 of 259) with videos related to

Pageof 26
Sort By:
Leukemia|January 17, 2003
Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised miceJ H Black, J A McCubrey, M C Willingham, et al.
Molecular Pharmacology|December 16, 2016
Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant CellsJacqueline Thorburn, Leah Staskiewicz, Megan L Goodall, et al.
Plos One|October 23, 2010
Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanismMachender R Kandadi, Yinan Hua, Heng Ma, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Cancer Research|April 6, 2007
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude miceYunpeng Su, Janelle Ortiz, Shihui Liu, et al.
Bioconjugate Chemistry|July 21, 1998
Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSFA E Frankel, P D Hall, C McLain, et al.
Anti-Cancer Drugs|September 30, 2011
Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cellsVaidehi Agrawal, Jung Hee Woo, Jeremy P Mauldin, et al.
Molecular Cancer Therapeutics|September 20, 2005
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxinRalph J Abi-Habib, Jeffrey O Urieto, Shihui Liu, et al.
Cancer Research|October 1, 1986
Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patientsP S Linsley, V Ochs, S Laska, et al.
The Journal of Surgical Research|January 1, 1995
Upregulation of b-FGF receptor expression after carotid bypassT E Brothers, J G Robison, B M Elliott, et al.
Pageof 26

Showing results (161-170 of 259) with videos related to

Sort By:
Pageof 26
Leukemia|January 17, 2003
Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised miceJ H Black, J A McCubrey, M C Willingham, et al.
Molecular Pharmacology|December 16, 2016
Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant CellsJacqueline Thorburn, Leah Staskiewicz, Megan L Goodall, et al.
Plos One|October 23, 2010
Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanismMachender R Kandadi, Yinan Hua, Heng Ma, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Cancer Research|April 6, 2007
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude miceYunpeng Su, Janelle Ortiz, Shihui Liu, et al.
Bioconjugate Chemistry|July 21, 1998
Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSFA E Frankel, P D Hall, C McLain, et al.
Anti-Cancer Drugs|September 30, 2011
Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cellsVaidehi Agrawal, Jung Hee Woo, Jeremy P Mauldin, et al.
Molecular Cancer Therapeutics|September 20, 2005
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxinRalph J Abi-Habib, Jeffrey O Urieto, Shihui Liu, et al.
Cancer Research|October 1, 1986
Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patientsP S Linsley, V Ochs, S Laska, et al.
The Journal of Surgical Research|January 1, 1995
Upregulation of b-FGF receptor expression after carotid bypassT E Brothers, J G Robison, B M Elliott, et al.
Pageof 26